Papillary Thyroid Carcinoma Variants

被引：192
作者：
Lloyd R.V. [1 ]
Buehler D. [1 ]
Khanafshar E. [2 ]
机构：
[1] Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, 600 Highland Avenue
[2] Department of Pathology, University of California School of Medicine, San Francisco, CA
来源：
Head and Neck Pathology | 2011年 / 5卷 / 1期
关键词：
BRAF mutation; Columnar cell; Follicular variant; HMGA2; Papillary thyroid carcinoma; RET/PTC; Tall cell;
D O I：
10.1007/s12105-010-0236-9
中图分类号：
学科分类号：
摘要：
Papillary thyroid carcinomas are the most common thyroid cancers and constitute more than 70% of thyroid malignancies. The most common etiologic factor is radiation, but genetic susceptibility and other factors also contribute to the development of papillary thyroid carcinoma. The most common variants include conventional, follicular variant and tall cell variant. However, many other uncommon variants have been described including oncocytic, columnar cell, diffuse sclerosing and solid forms. Immunohistochemical staining with TTF-1 and thyroglobulin is very useful in confirming the diagnosis of papillary thyroid carcinoma especially in metastatic sites. Markers such as HBME-1 and CITED1 can assist in separating some difficult cases of follicular variants of papillary thyroid carcinomas from follicular adenomas. Molecular studies have shown that the BRAF V600E mutation is found mainly in papillary and anaplastic thyroid carcinomas. Other molecular markers such as HMGA2 and insulin-like growth factor II mRNA binding protein 3 have been used recently as molecular tests to separate papillary thyroid carcinoma and its variants from follicular adenomas and other benign thyroid nodules. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码：51 / 56
页数：5
相关论文
共 20 条
  • [1] Khan A., Nose V., Endocrine pathology: Differential diagnosis and molecular advances, pp. 181-236, (2010)
  • [2] Pathology and genetics of tumours of endocrine organs., (2004)
  • [3] Hemminiki K., Li X., Familial risk of cancer by site and histopathology, Int J Cancer, 103, pp. 105-109, (2003)
  • [4] Isaacs J.D., Lundgren C.I., Sidhu S.B., Et al., The Delphian lymph node in thyroid cancer, Ann Surg, 247, pp. 477-482, (2008)
  • [5] Wallander M., Layfield L.J., Jarboe E., Et al., Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts, Appl Immunohistochem Mol Morphol, 18, pp. 231-235, (2010)
  • [6] Lloyd R.V., Erickson L.A., Casey M.B., Et al., Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma, Am J Surg Pathol, 28, pp. 1336-1340, (2004)
  • [7] Rivera M., Ricarte-Filho J., Patel S., Et al., Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopthologic and molecular study, Hum Pathol, 41, pp. 172-180, (2010)
  • [8] Hawk W.A., Hazard J.B., The many appearances of papillary carcinoma of the thyroid, Cleve Clin Q, 43, pp. 207-215, (1976)
  • [9] Johnson T.L., Lloyd R.V., Thompson N.W., Et al., Prognostic implications of the tall cell variant of papillary thyroid carcinoma, Am J Surg Pathol, 12, pp. 22-27, (1988)
  • [10] Herrera M.F., Hay I.D., Wu P.S., Et al., Hurthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior, World J Surg, 16, pp. 669-674, (1992)
12